ArticleMediators of inflammation2026
Miacalcic Enhances Rotator Cuff Injury Healing in Osteoporotic Mice by Stimulating Neovascularization via the JAK Pathway.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Miacalcic Enhances Rotator Cuff Injury Healing in Osteoporotic Mice by Stimulating Neovascularization via the JAK Pathway.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveRotator cuff tears (RCT) are prevalent among the elderly and often lead to significant shoulder pain. While both open and arthroscopic cuff repairs are effective, the recurrence of RCT post-surgery remains high, with osteoporosis being a major contributing risk factor. Local angiogenesis and tendon-bone healing are essential for optimal recovery after rotator cuff repair. This study investigates the effects of Miacalcic, an osteoporosis medication, on rotator cuff repair in osteoporotic conditions.
methodsTo explore the mechanisms underlying Miacalcic's action, we conducted RNA-sequencing and cell-based experiments on bone marrow-derived mesenchymal stem cells (BMSC) and human umbilical vein endothelial cells (HUVECs). Additionally, an osteoporotic mouse model of RCT was utilized to assess in vivo effects.
resultsOur findings revealed that Miacalcic had no significant effect on the proliferation of BMSCs, whereas it notably stimulated the proliferation of HUVECs. Miacalcic also significantly reduced apoptosis in HUVECs and enhanced their angiogenic potential. RNA-Seq analysis indicated that Miacalcic primarily modulates the JAK signaling pathway, which plays a key role in angiogenesis. In vivo, Miacalcic treatment in an osteoporotic mouse model enhanced vascularization and facilitated tendon-bone healing in the rotator cuff, leading to improved functional recovery following RCT.
conclusionThis study highlights the potential of Miacalcic as a therapeutic agent for promoting tendon-bone healing in osteoporotic patients with rotator cuff injuries. By elucidating the mechanisms through which Miacalcic enhances angiogenesis and healing, our findings offer insights into potential strategies for improving post-operative outcomes and reducing RCT recurrence. Further research is necessary to refine our understanding of the specific biological pathways involved and to explore the long-term therapeutic benefits of Miacalcic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.